Answers are grounded in this paper and cite their sources.
Extraventricular neurocytoma (EVN) is a rare neuronal tumor arising within the brain parenchyma outside the ventricular system. Although traditionally regarded as a low-grade neoplasm with favorable prognosis following gross total resection, accumulating evidence suggests considerable biological heterogeneity. The 2021 World Health Organization (WHO) classification of central nervous system tumors introduced an integrated histomolecular diagnostic framework, emphasizing the role of molecular alterations in tumor classification and prognostic stratification. In this context, EVN represents a diagnostically challenging entity due to morphological overlap with other low-grade neuroepithelial tumors, particularly oligodendroglioma. This narrative review summarizes current knowledge regarding the clinicopathologic features, molecular landscape, and clinical implications of EVN. Available literature addressing histopathologic characteristics, genomic alterations, molecular classification, and therapeutic strategies was analyzed to provide an updated overview of EVN within the WHO CNS5 framework. Classical EVN is characterized by neuronal differentiation, uniform round cells, and synaptophysin positivity. However, a subset of tumors demonstrates atypical features such as increased mitotic activity, elevated Ki-67 proliferation index, necrosis, or microvascular proliferation, which are associated with higher recurrence risk. Molecular studies have identified recurrent alterations, most notably FGFR1 rearrangements including FGFR1-TACC1 fusions, further illustrating the molecular heterogeneity of tumors classified as EVN. DNA methylation profiling has further refined EVN classification, revealing discrepancies between morphology-based diagnoses and underlying molecular identity. Emerging evidence suggests that integrated molecular stratification may improve prognostic assessment. FGFR1 alterations have been identified in a subset of methylation-defined EVNs and have been associated with a comparatively indolent clinical course in limited retrospective datasets; however, their biological and prognostic significance requires further validation. EVN should be considered a biologically heterogeneous tumor spectrum rather than a uniform clinicopathologic entity. Integration of histologic and molecular data may improve diagnostic accuracy, contribute to prognostic assessment, and support the future development of targeted therapeutic strategies. Standardized molecular testing and prospective multicenter studies will be critical for improving risk stratification and optimizing management of this rare tumor.
No takes yet. Share an insight, caveat, or question.
Maryńczak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: